Comparing Insulin Degludec And Insulin Glargine
Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia - low blood sugar - compared with the commercially available insulin glargine, a new meta-analysis study finds. Results of the combined analysis, of five completed clinical trials, were presented at The Endocrine Society's 95th Annual Meeting in San Francisco. The studies included nearly 3,400 adults with type 2 diabetes who had a daily injection of either insulin degludec or glargine combined with either a mealtime insulin or oral diabetic medications... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 20, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
Lantus (Insulin Glargine [rDNA origin] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 17, 2013 Category: Drugs & Pharmacology Source Type: news
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013 (EMA press release, 31 May 2013)
The European Medicines Agency (EMA) has published the latest news from its Committee for Medicinal Products for Human Use, including updates on Somatropin Biopartners for endogenous growth hormone deficiency, its review of new safety data on insulin glargine, an application to modify the approved use of Lysodren (mitotane) and a Q&A on withdrawal of the marketing authorisation application for
Belviq (lorcaserin).
Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 3, 2013 Category: Endocrinology Source Type: news
No Cancer Risk With Insulin Glargine, Says EMANo Cancer Risk With Insulin Glargine, Says EMA
The European Medicines Agency has concluded there is no increased risk of cancer associated with insulin-glargine products. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Degludec Shows Efficacy in Type 1 Diabetes (CME/CE)
PHOENIX (MedPage Today) -- Type 1 diabetes patients had lower rates of nocturnal hypoglycemia when receiving once-daily doses of insulin degludec compared with similar doses of insulin glargine, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 3, 2013 Category: Cardiology Source Type: news
Insulin has small effect on IMT, fish oil has none: GRACE
In patients with early type 2 diabetes with a high risk of CVD, insulin glargine modestly reduced progression in carotid artery intima media thickness; omega-3 fatty-acid supplements did not. (Source: theHeart.org)
Source: theHeart.org - April 13, 2013 Category: Cardiology Source Type: news
Insulin Has Small Effect, Fish Oil Has None on IMT: GRACEInsulin Has Small Effect, Fish Oil Has None on IMT: GRACE
In patients with early type 2 diabetes with a high risk of CVD, insulin glargine modestly reduced progression in carotid artery intima media thickness; omega-3 fatty-acid supplements did not. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Basal bolus versus basal plus correction insulin regimen for the management of medical and surgical patients with type 2 diabetes
Source: Diabetes Care
Area: News
According to the results of a prospective, multicentre, open-label study published early online in Diabetes Care, the use of a 'basal plus' regimen of insulin (glargine once daily plus corrective doses of glulisine insulin before meals) in the management of general medical and surgical patients with type 2 diabetes results in similar glycaemic control to a standard basal bolus regimen. According to the authors, recent randomised trials have shown that use of a basal bolus insulin regimen for patients with type 2 diabetes who are admitted to general medicine and surgery wards results in low...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
In Europe, Insulin Degludec to Cost 60-70% More Than LantusIn Europe, Insulin Degludec to Cost 60-70% More Than Lantus
Denmark's Novo Nordisk, the world's biggest insulin producer, will sell its long-acting insulin degludec (Tresiba) in Europe at a 60-70% premium over rival product Lantus from France's Sanofi. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 15, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Novo to sell Tresiba in Europe at 60-70 percent premium over Lantus
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, will sell its long-acting insulin Tresiba in Europe at a 60-70 percent premium over rival product Lantus from France's Sanofi. (Source: Reuters: Health)
Source: Reuters: Health - February 15, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Insulin Analogues Dosing and Costs -- Detemir vs GlargineInsulin Analogues Dosing and Costs -- Detemir vs Glargine
Which analog is more cost-effective? Insulin detemir or insulin glargine? BMC Endocrine Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 28, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Horizon scanning: Afrezza Inhaled Insulin for Diabetes Mellitus
Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This bulletin from the Canadian Agency for Drugs and Technologies in Health (CADTH) discusses investigational inhaled insulin, Afrezza, which consists of Technosphere insulin (TI) inhalation powder and a product-specific breath-activated inhaler. TI cartridges are used with an inhaler one minute before eating for managing type 1 and type 2- diabetes.
Findings from trials include the following:
. TI reduces postprandial glucose and HbA1c levels in type 2 diabetes patients taking oral antidiabetic drugs or concurrent i...
Source: NeLM - News - January 24, 2013 Category: Drugs & Pharmacology Source Type: news
EC approves marketing authorisation for insulin degludec
Source: PharmaTimes
Area: News
According to a report by PharmaTimes, the European Commission (EC) has approved marketing authorisation for insulin degludec (Tresiba) and insulin-degludec in combination with insulin aspart (Ryzodeq).
Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin. The manufacturer claims that insulin degludec is associated with a lower risk of nocturnal hypoglycaemia when compared with insulin glargine. However, despite positive effects on nocturnal hypoglycaemia overall hypoglycaemia remained the most common si...
Source: NeLM - News - January 22, 2013 Category: Drugs & Pharmacology Source Type: news
